EXACT Sciences Co. (EXAS) Price Target Raised to $46.00 – BNB Daily (blog)

This post was originally published on this site

EXACT Sciences Co. (NASDAQ:EXAS) had its price objective boosted by Roth Capital from $40.00 to $46.00 in a research note published on Wednesday, July 26th. They currently have a buy rating on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. Craig Hallum lifted their price objective on EXACT Sciences from $35.00 to $41.00 in a report on Friday, July 7th. Leerink Swann set a $38.00 price objective on EXACT Sciences and gave the stock a buy rating in a report on Friday, April 28th. Bank of America Corporation reaffirmed a buy rating on shares of EXACT Sciences in a report on Wednesday, March 29th. Jefferies Group LLC reaffirmed a buy rating and set a $25.00 price objective on shares of EXACT Sciences in a report on Wednesday, April 26th. Finally, Canaccord Genuity reaffirmed a buy rating and set a $27.00 price objective on shares of EXACT Sciences in a report on Monday, April 24th. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. EXACT Sciences presently has a consensus rating of Buy and a consensus price target of $40.51.

EXACT Sciences (NASDAQ EXAS) traded up 1.92% during mid-day trading on Wednesday, hitting $37.76. The stock had a trading volume of 1,183,339 shares. The stock has a 50-day moving average price of $37.62 and a 200 day moving average price of $28.82. EXACT Sciences has a 12-month low of $13.05 and a 12-month high of $42.18. The firm’s market cap is $4.50 billion.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. EXACT Sciences had a negative return on equity of 29.05% and a negative net margin of 53.41%. Equities analysts anticipate that EXACT Sciences will post ($1.18) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) Price Target Raised to $46.00” was posted by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/13/exact-sciences-corporation-exas-price-target-increased-to-46-00-by-analysts-at-roth-capital-updated-updated.html.

In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of EXACT Sciences stock in a transaction on Monday, July 31st. The stock was sold at an average price of $39.41, for a total value of $230,390.86. Following the completion of the sale, the chief financial officer now owns 19,861 shares of the company’s stock, valued at $782,722.01. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP D Scott Coward sold 1,987 shares of EXACT Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the completion of the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. 4.00% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. acquired a new stake in shares of EXACT Sciences during the second quarter worth approximately $106,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of EXACT Sciences by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after buying an additional 600 shares in the last quarter. Financial Architects Inc increased its stake in shares of EXACT Sciences by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares in the last quarter. Johnson Financial Group Inc. increased its stake in shares of EXACT Sciences by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after buying an additional 1,000 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in EXACT Sciences by 66.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock worth $179,000 after buying an additional 2,013 shares during the period. 84.86% of the stock is owned by institutional investors and hedge funds.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for EXACT Sciences Co. and related companies with MarketBeat.com’s FREE daily email newsletter.

This post was originally published on *this site*